(Q38072115)

28 August 2017

1 reference

title

Targeting IGF-1 signaling pathways in gynecologic malignancies (English)

1 reference

28 August 2017

1

Ilan Bruchim

1 reference

28 August 2017

Haim Werner

2

1 reference

28 August 2017

language of work or name

English

0 references

publication date

7 January 2013

1 reference

Expert Opinion on Therapeutic Targets

28 August 2017

published in

1 reference

28 August 2017

volume

17

1 reference

28 August 2017

issue

3

1 reference

28 August 2017

page(s)

307-320

1 reference

Insulin and insulin-like growth factor signalling in neoplasia

28 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.749863

Mechanisms of disease: metabolic effects of growth hormone and insulin-like growth factor 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.749863

The insulin-like growth factor-I receptor as an oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.749863

Molecular and cellular aspects of the insulin-like growth factor I receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.749863

Heterodimerization of glycosylated insulin-like growth factor-1 receptors and insulin receptors in cancer cells sensitive to anti-IGF1R antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.749863

The type 1 insulin-like growth factor receptor pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.749863

Simian virus 40 large tumor antigen is unable to transform mouse embryonic fibroblasts lacking type 1 insulin-like growth factor receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.749863

Effect of a null mutation of the insulin-like growth factor I receptor gene on growth and transformation of mouse embryo fibroblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.749863

Targeting insulin-like growth factor 1 receptor in sarcomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.749863

Emerging role of insulin-like growth factor receptor inhibitors in oncology: early clinical trial results and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.749863

Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.749863

Circulating Insulin-Like Growth Factor-I and Binding Protein-3 and the Risk of Breast Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.749863

IGF-I, IGFBP-3 and breast cancer risk in women: The European Prospective Investigation into Cancer and Nutrition (EPIC)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.749863

Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.749863

The IGF-I receptor in cancer research

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.749863

Insulin-like growth factors promote vasculogenesis in embryonic stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.749863

The role of the IGF system in cancer growth and metastasis: overview and recent insights

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.749863

Targeting the insulin-like growth factor receptor: developing biomarkers from gene expression profiling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.749863

Wild-type and mutant p53 differentially regulate transcription of the insulin-like growth factor I receptor gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.749863

The p53-family members p63 and p73 inhibit insulin-like growth factor-I receptor gene expression in colon cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.749863

BRCA1 suppresses insulin-like growth factor-I receptor promoter activity: potential interaction between BRCA1 and Sp1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.749863

BRCA1–Sp1 interactions in transcriptional regulation of the IGF‐IR gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.749863

Functional and physical interactions between BRCA1 and p53 in transcriptional regulation of the IGF-IR gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.749863

Insulin-like growth factor: current concepts and new developments in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.749863

Clinical development of inhibitors of the insulin-like growth factor receptor in oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.749863

Targeting the IGF1 axis in cancer proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.749863

In vivo effects of the human type I insulin-like growth factor receptor antibody A12 on androgen-dependent and androgen-independent xenograft human prostate tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.749863

AMG 479, a fully human anti-insulin-like growth factor receptor type I monoclonal antibody, inhibits the growth and survival of pancreatic carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.749863

The insulin-like growth factor-I receptor inhibitor figitumumab (CP-751,871) in combination with docetaxel in patients with advanced solid tumours: results of a phase Ib dose-escalation, open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.749863

Targeting the insulin-like growth factor axis for the development of novel therapeutics in oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.749863

Blocking the insulin-like growth factor-I receptor as a strategy for targeting cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.749863

IGF-1 receptor inhibitors in clinical trials--early lessons

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.749863

In vivo antitumor activity of NVP-AEW541-A novel, potent, and selective inhibitor of the IGF-IR kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.749863

Cyclolignans as inhibitors of the insulin-like growth factor-1 receptor and malignant cell growth.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.749863

Dual IGF-I/II-neutralizing antibody MEDI-573 potently inhibits IGF signaling and tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.749863

Targeting the Insulin-Like Growth Factor 1 Receptor in Ewing's Sarcoma: Reality and Expectations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.749863

Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.749863

Insulin-like growth factor type 1 receptor (IGF-1R) exclusive nuclear staining: a predictive biomarker for IGF-1R monoclonal antibody (Ab) therapy in sarcomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.749863

The insulin receptor substrate-1: a biomarker for cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.749863

Insulin-like growth factor II mediates epidermal growth factor-induced mitogenesis in cervical cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.749863

Plasma levels of insulin-like growth factor-1 and insulin-like growth factor binding protein-3 in women with cervical neoplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.749863

Cervical scrapes levels of insulin-like growth factor-II and insulin-like growth factor binding protein 3 in women with squamous intraepithelial lesions and cervical cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.749863

Insulin-like growth factor II in gynecological cancers: a preliminary study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.749863

Differential expression of IGF-I and insulin receptor isoforms in HPV positive and negative human cervical cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.749863

Insulin-like growth factor axis and oncogenic human papillomavirus natural history

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.749863

Insulin-like growth factor 1 is a potent stimulator of cervical cancer cell invasiveness and proliferation that is modulated by alphavbeta3 integrin signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.749863

Gene expression changes in cervical squamous cell carcinoma after initiation of chemoradiation and correlation with clinical outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.749863

Clinical implications of insulin-like growth factor 1 system in early-stage cervical cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.749863

21 January 2018

Cancer statistics, 2009

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.749863

Two pathogenetic types of endometrial carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.749863

Molecular genetic pathways in various types of endometrial carcinoma: from a phenotypical to a molecular-based classification

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.749863

Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.749863

The metabolic syndrome, IGF-1, and insulin action

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.749863

IGF and insulin receptor signaling in breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.749863

Specific binding and growth-promoting activity of insulin in endometrial cancer cells in culture

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.749863

Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.749863

Interactions between IGF-I, estrogen receptor-α (ERα), and ERβ in regulating growth/apoptosis of MCF-7 human breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.749863

BRCA1 is expressed in uterine serous carcinoma (USC) and controls insulin-like growth factor I receptor (IGF-IR) gene expression in USC cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.749863

Endometrial cancer and the IGF system: a case-control study in Greece

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.749863

A prospective evaluation of insulin and insulin-like growth factor-I as risk factors for endometrial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.749863

Serum levels of insulin-like growth factor-I, IGF-binding protein 1 and 3, and insulin and endometrial cancer risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.749863

Insulin-like growth factor 2 and its receptors (IGF 1R and IGF 2R/mannose 6-phosphate) in endometrial adenocarcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.749863

Common genetic variation within IGFI, IGFII, IGFBP-1, and IGFBP-3 and endometrial cancer risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.749863

Insulin-like growth factor-I receptor inhibition by specific tyrosine kinase inhibitor NVP-AEW541 in endometrioid and serous papillary endometrial cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.749863

Insulin-like growth factor-I receptor (IGF-IR) targeting with monoclonal antibody cixutumumab (IMC-A12) inhibits IGF-I action in endometrial cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.749863

AMG 479, a novel IGF-1-R antibody, inhibits endometrial cancer cell proliferation through disruption of the PI3K/Akt and MAPK pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.749863

Inhibitory effect of siRNA targeting IGF-1R on endometrial carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.749863

Down-regulation of IGF-1R expression inhibits growth and enhances chemosensitivity of endometrial carcinoma in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.749863

A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.749863

A phase 3 trial of bevacizumab in ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.749863

OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.749863

Insulin-like growth factor receptor I targeting in epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.749863

Circulating levels of insulin-like growth factor-I and risk of ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.749863

Serum insulin-like growth factor (IGF)-I, IGF binding protein (IGFBP)-3, leptin concentrations and insulin resistance in benign and malignant epithelial ovarian tumors in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.749863

Common genetic variation in IGF1, IGFBP1 and IGFBP3 and ovarian cancer risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.749863

Genetic variation in insulin-like growth factor 2 may play a role in ovarian cancer risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.749863

Increase in docetaxel-resistance of ovarian carcinoma-derived RMG-1 cells with enhanced expression of Lewis Y antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.749863

High insulin-like growth factor-2 (IGF-2) gene expression is an independent predictor of poor survival for patients with advanced stage serous epithelial ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.749863

The insulin-like growth factor 1 pathway is a potential therapeutic target for low-grade serous ovarian carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.749863

IGF axis gene expression patterns are prognostic of survival in epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.749863

Hyperactivation of the insulin-like growth factor receptor I signaling pathway is an essential event for cisplatin resistance of ovarian cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.749863

Insulin-like growth factor 2 expression modulates Taxol resistance and is a candidate biomarker for reduced disease-free survival in ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.749863

Ovarian cancer: Stat3, RhoA and IGF-IR as therapeutic targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.749863

BMS-536924 sensitizes human epithelial ovarian cancer cells to the PARP inhibitor, 3-aminobenzamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.749863

Targeting the insulin growth factor and the vascular endothelial growth factor pathways in ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.749863

Circulating concentrations of insulin-like growth factor I and risk of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.749863

Potential Applications for Circulating Tumor Cells Expressing the Insulin-Like Growth Factor-I Receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.749863

10.1517/14728222.2013.749863

21 January 2018

Identifiers

DOI

1 reference

28 August 2017

1 reference